Marcus Butler

Featured in: Favicon

nature.com Favicon

frontiersin.org Favicon

jacionline.org Favicon

medicinejournal.co.uk

Articles

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results - Nature Medicine

Jul 27, 2023 | nature.com | Raffit Hassan |Marcus Butler |Roisin E. O’Cearbhaill |Melissa Johnson |Nirali Shah |Babak Saboury | +2 more

AbstractThe T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →